# A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)

> **NCT02110901** · PHASE3 · COMPLETED · sponsor: **Proteon Therapeutics** · enrollment: 349 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** PRT-201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02110901
- **Lead sponsor:** Proteon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-12
- **Final completion:** 2018-12
- **Target enrollment:** 349 (ACTUAL)
- **Last updated:** 2019-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02110901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02110901, "A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02110901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*